Background and Importance Brugada syndrome (BRS) is a rare inherited heart rhythm disorder characterised by ST-segment elevation and a potential risk of fatal arrhythmias. It is a disorder of transmembrane ion channels that predisposes to arrhythmias. Channelopathies are pure electrical diseases that are not associated with underlying structural heart disease, making early diagnosis difficult.

Aim and Objectives Review the literature related to contraindicated drugs in RBS; create an updated list to facilitate pharmaceutical validation in these patients and compare the list created with the known list of QT-modifying drugs.

Material and Methods A critical analysis of EMBASE and PUBMED studies was performed. The terms ‘brugada syndrome’ AND ‘drugs’ were used. Included studies met the following criteria: reviews, within the last 5 years and in humans only. The list of drugs described on the brugadadrugs.org website in 2017 was used as a preliminary basis. The medicines finally identified were classified into two groups, according to their level of risk. The group of contraindicated drugs (should not be used under any circumstances) and group of potentially dangerous drugs (with inconclusive data. Use should be evaluated on an individual basis). The list of QT-modifying drugs was obtained from the crediblemeds.org website and compared with the list of drugs identified for BRS.

Results Nine articles met the inclusion criteria. The medicines classified in both groups are shown in table.

The degree of agreement obtained with the list of QT-modifying drugs was 29.21%.

Conclusion and Relevance The low concordance with respect to the list of QT-modifying drugs makes it necessary to define a specific drug list for patients with RBS. This could improve the quality of treatment validation by the hospital pharmacist.

Conflict of Interest No conflict of interest